Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Prostatic Neoplasms 1ER+HER2- Breast Cancer 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × 18-O-demethylcervinomycin A2 × 1 year × Clear all
NCT07371208 2026-01-27

ST-A-TN

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms

NCT07179783 2025-09-18

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Tianjin Medical University Second Hospital

Phase 2 Recruiting
28 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07109284 2025-08-07

NeoSaciA

West China Hospital

Phase 2 Not yet recruiting
55 enrolled
Breast

ER+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡